References

 

 
Meeter LHH, et al. Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers. Ann Clin Transl Neurol. 2018 Apr 6;5(5):583-597. doi: 10.1002/acn3.559. eCollection 2018 May.

Li JQ, et al.,  Genome-wide association study identifies two loci influencing plasma neurofilament light levels. Alzheimer’s Disease Neuroimaging Initiative. BMC Med Genomics. 2018 May 10;11(1):47. doi: 10.1186/s12920-018-0364-8.

Pinter D, et al., Longitudinal MRI dynamics of recent small subcortical infarcts and possible predictors. J Cereb Blood Flow Metab. 2018 Jan 1:271678X18775215. doi: 10.1177/0271678X18775215. [Epub ahead of print]

Wilke C, et al., Serum neurofilament light is increased in multiple system atrophy of cerebellar type and in repeat-expansion spinocerebellar ataxias: a pilot study. J Neurol. 2018 May 8. doi: 10.1007/s00415-018-8893-9. [Epub ahead of print]

Bergman L, et al., Blood-based cerebral biomarkers in preeclampsia: Plasma concentrations of NfL, tau, S100B and NSE during pregnancy in women who later develop preeclampsia – A nested case control study. PLoS One. 2018 May 2;13(5):e0196025. doi: 10.1371/journal.pone.0196025. eCollection 2018.

Kawata K, et al., A Preliminary Report on Brain-Derived Extracellular Vesicle as Novel Blood Biomarkers for Sport-Related Concussions. Front Neurol. 2018 Apr 12;9:239. doi: 10.3389/fneur.2018.00239. eCollection 2018.

Osborn KE, et al., Cerebrospinal fluid β-amyloid42 and neurofilament light relate to white matter hyperintensities. Neurobiol Aging. 2018 Apr 3;68:18-25. doi: 10.1016/j.neurobiolaging.2018.03.028. [Epub ahead of print]

Korley FK, et al., Performance Evaluation of a Multiplex Assay for Simultaneous Detection of Four Clinically Relevant TBI Biomarkers. J Neurotrauma. 2018 Apr 25. doi: 10.1089/neu.2017.5623. [Epub ahead of print]

Evers KS, et al., Neurofilament as Neuronal Injury Blood Marker in Preeclampsia. Hypertension. 2018 Jun;71(6):1178-1184. doi: 10.1161/HYPERTENSIONAHA.117.10314. Epub 2018 Apr 23.

Shahim P, et al., Neurofilament light and tau as blood biomarkers for sports-related concussion. Neurology. 2018 May 15;90(20):e1780-e1788. doi: 10.1212/WNL.0000000000005518. Epub 2018 Apr 13.

Arulsamy A, et al., Evaluation of early chronic functional outcomes and their relationship to pre-frontal cortex and hippocampal pathology following moderate-severe traumatic brain injury. Behav Brain Res. 2018 Apr 10;348:127-138. doi: 10.1016/j.bbr.2018.04.009. [Epub ahead of print]

Strydom A, et al., LonDownS Consortium. Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome. Alzheimers Res Ther. 2018 Apr 10;10(1):39. doi: 10.1186/s13195-018-0367-x.

Chatterjee P, et al., Association of Plasma Neurofilament Light Chain with Neocortical Amyloid-β Load and Cognitive Performance in Cognitively Normal Elderly Participants. J Alzheimers Dis. 2018;63(2):479-487. doi: 10.3233/JAD-180025.

Axelsson M, et al., Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-Barré syndrome: A pilot study. Acta Neurol Scand. 2018 Apr 6. doi: 10.1111/ane.12927. [Epub ahead of print]

Novakova L, et al., Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers. PLoS One. 2018 Apr 3;13(4):e0194828. doi: 10.1371/journal.pone.0194828. eCollection 2018.

Goossens J, et al., Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration. Alzheimers Res Ther. 2018 Mar 20;10(1):31. doi: 10.1186/s13195-018-0364-0.

Paterson RW, et al., Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. Alzheimers Res Ther. 2018 Mar 20;10(1):32. doi: 10.1186/s13195-018-0361-3.

Shah DK, et al., Raised Plasma Neurofilament Light Protein Levels Are Associated with Abnormal MRI Outcomes in Newborns Undergoing Therapeutic Hypothermia. Front Neurol. 2018 Mar 5;9:86. doi: 10.3389/fneur.2018.00086. eCollection 2018.

Ridler C. Prion disease: Dramatic increases in blood levels of tau and neurofilament light in patients with prion disease. Nat Rev Neurol. 2018 May;14(5):252. doi: 10.1038/nrneurol.2018.34. Epub 2018 Mar 16. No abstract available.

Siller N, et al., Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. Mult Scler. 2018 Mar 1:1352458518765666. doi: 10.1177/1352458518765666. [Epub ahead of print]

Meeter LHH, et al., Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. Neurology. 2018 Apr 3;90(14):e1231-e1239. doi: 10.1212/WNL.0000000000005261. Epub 2018 Mar 7.

Hampel H, et al., Alzheimer’s disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ1-42, total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40. Alzheimer Precision Medicine Initiative (APMI). Alzheimers Dement. 2018 Apr;14(4):492-501. doi: 10.1016/j.jalz.2017.11.015. Epub 2018 Jan 9.

Johnson EB TRACK-HD Study Group et al., Neurofilament light protein in blood predicts regional atrophy in Huntington disease. Neurology. 2018 Feb 20;90(8):e717-e723. doi: 10.1212/WNL.0000000000005005. Epub 2018 Jan 24.

Abu-Rumeileh S, et al., The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias. Alzheimers Res Ther. 2018 Jan 11;10(1):3. doi: 10.1186/s13195-017-0331-1.

Zerr I, et al., Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. Alzheimers Dement. 2018 Feb 3. pii: S1552-5260(18)30002-5. doi: 10.1016/j.jalz.2017.12.008. [Epub ahead of print]

Al-Khaled M. Serum neurofilament light as diagnostic biomarker for acute cerebral ischemia: a promising tool. Eur J Neurol. 2018 Apr;25(4):609. doi: 10.1111/ene.13588. Epub 2018 Feb.

Korley FK, et al., Valproic Acid Treatment Decreases Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels in Swine Subjected to Traumatic Brain Injury. J Neurotrauma. 2018 May 15;35(10):1185-1191. doi: 10.1089/neu.2017.5581. Epub 2018 Mar 13.

Olsson M, et al., Sleep deprivation and cerebrospinal fluid biomarkers for Alzheimer’s disease. Sleep. 2018 May 1;41(5). doi: 10.1093/sleep/zsy025.

Bettcher BM, et al., Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer’s Disease Pathology and Neuronal Damage. J Alzheimers Dis. 2018;62(1):385-397. doi: 10.3233/JAD-170602.

Foiani MS, et al., Plasma tau is increased in frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2018 Feb 13. pii: jnnp-2017-317260. doi: 10.1136/jnnp-2017-317260. [Epub ahead of print]

Matute-Blanch C, et al., Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain. 2018 Apr 1;141(4):1085-1093. doi: 10.1093/brain/awy021.

Evered L, et al., Association of Changes in Plasma Neurofilament Light and Tau Levels With Anesthesia and Surgery: Results From the CAPACITY and ARCADIAN Studies. JAMA Neurol. 2018 May 1;75(5):542-547. doi: 10.1001/jamaneurol.2017.4913.

Wellington H, et al., CSF neurogranin or tau distinguish typical and atypical Alzheimer disease. Ann Clin Transl Neurol. 2018 Jan 11;5(2):162-171. doi: 10.1002/acn3.518. eCollection 2018 Feb.

Niemelä V, et al., Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington’s disease. PLoS One. 2018 Feb 23;13(2):e0193492. doi: 10.1371/journal.pone.0193492. eCollection 2018.

Rossi D, et al., CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis. J Neurol. 2018 Mar;265(3):510-521. doi: 10.1007/s00415-017-8730-6. Epub 2018 Jan 10.

Sandelius Å, et al., Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology. 2018 Feb 6;90(6):e518-e524. doi: 10.1212/WNL.0000000000004932. Epub 2018 Jan 10.

Moreau C, et al., Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis? Antioxid Redox Signal. 2018 Feb 8. doi: 10.1089/ars.2017.7493. [Epub ahead of print]

Rojas JC, et al., CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology. 2018 Jan 23;90(4):e273-e281. doi: 10.1212/WNL.0000000000004859. Epub 2017 Dec 27.

De Marchis GM, et al., Serum neurofilament light chain in patients with acute cerebrovascular events. Eur J Neurol. 2018 Mar;25(3):562-568. doi: 10.1111/ene.13554. Epub 2018 Jan 24.

Scott G, et al., Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration. Brain. 2018 Feb 1;141(2):459-471. doi: 10.1093/brain/awx339.

Tejeda-Velarde A, et al., Clinical usefulness of prognostic biomarkers in optic neuritis. Eur J Neurol. 2018 Apr;25(4):614-618. doi: 10.1111/ene.13553. Epub 2018 Feb 6.

Cheng WH, et al., Age at injury and genotype modify acute inflammatory and neurofilament-light responses to mild CHIMERA traumatic brain injury in wild-type and APP/PS1 mice. Exp Neurol. 2018 Mar;301(Pt A):26-38. doi: 10.1016/j.expneurol.2017.12.007. Epub 2017 Dec 18.

Rostgaard N, et al., CSF neurofilament light concentration is increased in presymptomatic CHMP2B mutation carriers. Neurology. 2018 Jan 9;90(2):e157-e163. doi: 10.1212/WNL.0000000000004799. Epub 2017 Dec 13.

Feneberg E, et al., Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology. 2018 Jan 2;90(1):e22-e30. doi: 10.1212/WNL.0000000000004761. Epub 2017 Dec 6.

Varhaug KN, et al., Neurofilament light chain predicts disease activity in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm. 2017 Nov 28;5(1):e422. doi: 10.1212/NXI.0000000000000422. eCollection 2018 Jan.

Marrie RA. Serum neurofilament light chain in relapsing-remitting MS: Unchaining disease activity prediction? Neurol Neuroimmunol Neuroinflamm. 2017 Nov 28;5(1):e421. doi: 10.1212/NXI.0000000000000421. eCollection 2018 Jan. No abstract available.

Mariotto S, et al., Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies Status. Mult Scler J Exp Transl Clin. 2017 Nov 22;3(4):2055217317743098. doi: 10.1177/2055217317743098. eCollection 2017 Oct-Dec.

Puz P, et al., Diagnostic methods used in searching for markers of atrophy in patients with multiple sclerosis. Neurol Res. 2018 Feb;40(2):110-116. doi: 10.1080/01616412.2017.1403729. Epub 2017 Nov 23.

Halawa I, et al., Seizures, CSF neurofilament light and tau in patients with subarachnoid haemorrhage. Acta Neurol Scand. 2018 Feb;137(2):199-203. doi: 10.1111/ane.12873. Epub 2017 Nov 21.

Al-Temaimi R, et al., Remyelination modulators in multiple sclerosis patients. Exp Mol Pathol. 2017 Dec;103(3):237-241. doi: 10.1016/j.yexmp.2017.11.004. Epub 2017 Nov 8.

Lycke J and Zetterberg H. The role of blood and CSF biomarkers in the evaluation of new treatments against multiple sclerosis. Expert Rev Clin Immunol. 2017 Dec;13(12):1143-1153. doi: 10.1080/1744666X.2017.1400380. Epub 2017 Nov 9.

Novakova L, et al., Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology. 2017 Nov 28;89(22):2230-2237. doi: 10.1212/WNL.0000000000004683. Epub 2017 Oct 27.

Soylu-Kucharz R, et al., Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington’s disease R6/2 mice. Sci Rep. 2017 Oct 26;7(1):14114. doi: 10.1038/s41598-017-14179-1.

Weston PSJ, et al., Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration. Neurology. 2017 Nov 21;89(21):2167-2175. doi: 10.1212/WNL.0000000000004667. Epub 2017 Oct 25.

van Zoest RA, et al.,  Structural Brain Abnormalities in Successfully Treated HIV Infection: Associations With Disease and Cerebrospinal Fluid Biomarkers. Comorbidity in Relation to AIDS (COBRA) Collaboration. J Infect Dis. 2017 Dec 27;217(1):69-81. doi: 10.1093/infdis/jix553.

Zetterberg H. Fluid biomarkers for microglial activation and axonal injury in multiple sclerosis. Acta Neurol Scand. 2017 Nov;136 Suppl 201:15-17. doi: 10.1111/ane.12845. Review.

Gattringer T, et al., Serum neurofilament light is sensitive to active cerebral small vessel disease. Neurology. 2017 Nov 14;89(20):2108-2114. doi: 10.1212/WNL.0000000000004645. Epub 2017 Oct 18.

Barro C, et al., Fluid biomarker and electrophysiological outcome measures for progressive MS trials. Mult Scler. 2017 Oct;23(12):1600-1613. doi: 10.1177/1352458517732844.

Fialova L, et al., Neurofilaments and tau proteins in cerebrospinal fluid and serum in dementias and neuroinflammation. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017 Sep;161(3):286-295. doi: 10.5507/bp.2017.038. Epub 2017 Sep 25.

Sellebjerg F, et al., Defining active progressive multiple sclerosis. Mult Scler. 2017 Nov;23(13):1727-1735. doi: 10.1177/1352458517726592. Epub 2017 Aug 23.

Kovacs GG, et al., Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology-based cohort. Eur J Neurol. 2017 Nov;24(11):1326-e77. doi: 10.1111/ene.13389. Epub 2017 Aug 16.

Skillbäck T, et al., CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients. Neurobiol Aging. 2017 Nov;59:1-9. doi: 10.1016/j.neurobiolaging.2017.06.028. Epub 2017 Jul 11.

Bischof A, et al., Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy. Ann Rheum Dis. 2017 Jul 25. pii: annrheumdis-2017-212045. doi: 10.1136/annrheumdis-2017-212045. [Epub ahead of print] No abstract available.

Reid SJ, et al., Alzheimer’s disease markers in the aged sheep (Ovis aries). Neurobiol Aging. 2017 Oct;58:112-119. doi: 10.1016/j.neurobiolaging.2017.06.020. Epub 2017 Jun 24.

Komori M, et al., Pharmacodynamic effects of daclizumab in the intrathecal compartment. Ann Clin Transl Neurol. 2017 May 29;4(7):478-490. doi: 10.1002/acn3.427. eCollection 2017 Jul.

Pereira JB, et al., Alzheimer’s Disease Neuroimaging Initiative. Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer’s disease. Neurobiol Aging. 2017 Oct;58:14-29. doi: 10.1016/j.neurobiolaging.2017.06.002. Epub 2017 Jun 17.

Sun B, et al., Blood neuron-derived exosomes as biomarkers of cognitive impairment in HIV. AIDS. 2017 Sep 10;31(14):F9-F17. doi: 10.1097/QAD.0000000000001595.

Sprecher KE, et al., Poor sleep is associated with CSF biomarkers of amyloid pathology in cognitively normal adults. Neurology. 2017 Aug 1;89(5):445-453. doi: 10.1212/WNL.0000000000004171. Epub 2017 Jul 5.

Skillbäck T, et al., Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Aug;18(5-6):397-403. doi: 10.1080/21678421.2017.1281962. Epub 2017 Feb 6.

Toorell H, et al., Increase of neuronal injury markers Tau and neurofilament light proteins in umbilical blood after intrapartum asphyxia. J Matern Fetal Neonatal Med. 2018 Sep;31(18):2468-2472. doi: 10.1080/14767058.2017.1344964. Epub 2017 Jul 9.

Byrne LM, et al., Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington’s disease: a retrospective cohort analysis. Lancet Neurol. 2017 Aug;16(8):601-609. doi: 10.1016/S1474-4422(17)30124-2. Epub 2017 Jun 7.

Jabbari E, et al., Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers. J Neurol Neurosurg Psychiatry. 2017 Oct;88(10):883-888. doi: 10.1136/jnnp-2017-315857. Epub 2017 Jun 9. Review.

Yilmaz A, et al., Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. Expert Rev Mol Diagn. 2017 Aug;17(8):761-770. doi: 10.1080/14737159.2017.1341313. Epub 2017 Jun 14.

Alcolea D, et al., CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration. Neurology. 2017 Jul 11;89(2):178-188. doi: 10.1212/WNL.0000000000004088. Epub 2017 Jun 7.

Lista S, et al., Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer’s disease. Alzheimer Precision Medicine Initiative (APMI). Neurochem Int. 2017 Sep;108:355-360. doi: 10.1016/j.neuint.2017.05.010. Epub 2017 May 17.

Kalm M, et al., Serum concentrations of the axonal injury marker neurofilament light protein are not influenced by blood-brain barrier permeability. Brain Res. 2017 Aug 1;1668:12-19. doi: 10.1016/j.brainres.2017.05.011. Epub 2017 May 15.

Isgren A, et al., Markers of neuroinflammation and neuronal injury in bipolar disorder: Relation to prospective clinical outcomes. Brain Behav Immun. 2017 Oct;65:195-201. doi: 10.1016/j.bbi.2017.05.002. Epub 2017 May 5.

Brureau A, et al., NF-L in cerebrospinal fluid and serum is a biomarker of neuronal damage in an inducible mouse model of neurodegeneration. Neurobiol Dis. 2017 Aug;104:73-84. doi: 10.1016/j.nbd.2017.04.007. Epub 2017 Apr 6.

Bagnato S, et al., Prolonged Cerebrospinal Fluid Neurofilament Light Chain Increase in Patients with Post-Traumatic Disorders of Consciousness. J Neurotrauma. 2017 Aug 15;34(16):2475-2479. doi: 10.1089/neu.2016.4837. Epub 2017 Jun 8.

Sellebjerg F, et al. Defining active progressive multiple sclerosis. Mult Scler. 2017 Aug 1.

Kovacs GG, et al. Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology-based cohort. Eur J Neurol. 2017 Aug 16.

Skillbäck T, et al. CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients. Neurobiol Aging. 2017 Jul 11;59:1-9.

Bischof A, et al. Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy. Ann Rheum Dis. 2017 Jul 25

Blennow K. A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood. Neurol Ther. 2017 Jul;6(Suppl 1):15-24.

Reid SJ, et al. Alzheimer’s disease markers in the aged sheep (Ovis aries). Neurobiol Aging. 2017 Oct;58:112-119.

Pereira JB, et al. Alzheimer’s Disease Neuroimaging Initiative. Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer’s disease. Neurobiol Aging. 2017 Oct;58:14-29.

Sprecher KE, et al. Poor sleep is associated with CSF biomarkers of amyloid pathology in cognitively normal adults. Neurology. 2017 Aug 1.

Skillbäck T, et al. Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Aug;18(5-6):397-403.

Toorell H, et al. Increase of neuronal injury markers Tau and neurofilament light proteins in umbilical blood after intrapartum asphyxia. J Matern Fetal Neonatal Med. 2017 Jul 9:1-5.

Piehl F, et al. Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Mult Scler. 2017 Jun 1.

Farotti L, et al. Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson’s disease. Expert Rev Mol Diagn. 2017 Aug;17(8):771-780.

Byrne LM, et al. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington’s disease: a retrospective cohort analysis. Lancet Neurol. 2017 Aug;16(8):601-609.

Racine AM, et al. Association of longitudinal white matter degeneration and cerebrospinal fluid biomarkers of neurodegeneration, inflammation and Alzheimer’s disease in late-middle-aged adults. Brain Imaging Behav. 2017 Jun 9.

Jabbari E, et al. Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers. J Neurol Neurosurg Psychiatry. 2017 Jun 9.

Yilmaz A, et al. Neurofilament light chain protein as amarker of neuronal injury: review of its use in HIV-1 infection and referencevalues for HIV-negative controls. Expert Rev Mol Diagn. 2017 Aug;17(8):761-770.

Alcolea D, et al. CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration. Neurology. 2017 Jul 11;89(2):178-188.

Tortorella C, et al. Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler. 2017 May 1.

Lista S, et al. Alzheimer Precision Medicine Initiative (APMI). Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer’s disease. Neurochem Int. 2017 Sep;108:355-360.

Kalm M et al. Serum concentrations of the axonal injury marker neurofilament light protein are not influenced by blood-brain barrier permeability. Brain Res. 2017 Aug 1;1668:12-19.

Disanto G, et al.  Swiss Multiple Sclerosis Cohort Study Group. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017 Jun;81(6):857-870.

Poesen K, et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology. 2017 Jun 13;88(24):2302-2309.

Isgren A, et al. Markers of neuroinflammation and neuronal injury in bipolar disorder: Relation to prospective clinical outcomes. Brain Behav Immun. 2017 Oct;65:195-201.

Clement A, et al. Cerebrospinal fluid neurofilament light chain as a biomarker of neurodegeneration in the Tg4510 and MitoPark mouse models. Neuroscience. 2017 Jun 23;354:101-109.

Shahim P, et al. Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports. Neurology. 2017 May 9;88(19):1788-1794.

Brureau A, et al. NF-L in cerebrospinal fluid and serum is a biomarker of neuronal damage in an inducible mouse model of neurodegeneration. Neurobiol Dis. 2017 Aug;104:73-84.

Constantinescu R, et al. Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignancies. J Neuroimmunol. 2017 May 15;306:25-30.

Bagnato S, et al. Prolonged Cerebrospinal Fluid Neurofilament Light Chain Increase in Patients with Post-Traumatic Disorders of Consciousness. J Neurotrauma. 2017 Aug 15;34(16):2475-2479.

Mattsson N et al. Alzheimer’s Disease Neuroimaging Initiative. Association of Plasma Neurofilament Light WithNeurodegeneration in Patients With Alzheimer Disease. JAMA Neurol. 2017 May 1;74(5):557-566.

Vijverberg EG, et al. Cerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatric disorders. Alzheimers Dement (Amst). 2017 Mar 2;7:99-106.

Gaiani A, et.al. Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis: Neurofilament Light Chain Levels in Definite Subtypes of Disease. JAMA Neurol. 2017 Mar 6.

Håkansson I, et al. Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis. Eur J Neurol. 2017 Mar 6.

Niemelä V, et al. Tau or neurofilament light-Which is the more suitable biomarker for Huntington’s disease? PLoS One. 2017 Feb 27;12(2).

Steinacker P, et al. Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias. Neurology. 2017 Mar 7;88(10):961-969.

Alves G, et al. Neurofilament light: A heavyweight diagnostic biomarker in neurodegenerative parkinsonism? Neurology. 2017 Mar 7;88(10):922-923.

Hansson O, et al. Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder. Neurology. 2017 Mar 7;88(10):930-937.

Kuhle J, et al. Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology. 2017 Feb 28;88(9):826-831.

Höglund K, et al. Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration. Transl Psychiatry. 2017 Jan 10;7(1).

Steinacker P, et al. Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. Sci Rep. 2016 Dec 8;6:38737.

Anesten B, et al. Blood-brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV. Neurol Neuroimmunol Neuroinflamm. 2016 Nov 9;3(6).

Shahim P, et al. Serum neurofilament light protein predicts clinical outcome in traumatic brain injury. Sci Rep. 2016 Nov 7;6:36791.

Steinacker P, et al. Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: Data from the German MND-net. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Feb;18(1-2):112-119.

Idland AV, et al. CSF neurofilament light levels predicthippocampal atrophy in cognitively healthy older adults. Neurobiol Aging. 2017 Jan;49:138-144.

Novakova L, et al. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis. J Neurochem. 2016 Oct 27.

Racine AM, et al. Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer’s Disease. J Alzheimers Dis. 2016 Oct 18;54(4):1395-1408.

Vinther-Jensen T, et al. Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease.Neurol Neuroimmunol Neuroinflamm. 2016 Sep 28;3(6).

Mellergård J, et al. Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis. Eur J Neurol. 2017 Jan;24(1):112-121.

Stilund M, et al. A multi-biomarker follow-up study of patients with multiple sclerosis. Brain Behav. 2016 Jul 11;6(9).

Miller AM, et al. Multicenter immunoassay validation of cerebrospinal fluid neurofilament light: a biomarker for neurodegeneration. Bioanalysis. 2016 Nov;8(21):2243-2254.

Rodrigues FB, et al. Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington’s Disease. PLoS One. 2016 Sep 22;11(9).

Shahim P, et al. Neurochemical Aftermath of Repetitive Mild Traumatic Brain Injury. JAMA Neurol. 2016 Nov 1;73(11):1308-1315.

Jennum PJ, et al. Cerebrospinal fluid biomarkers of neurodegeneration are decreasedor normal in narcolepsy. Sleep. 2016 Sep 9. pii: sp-00139-16.

Rohrer JD, et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia.Neurology. 2016 Sep 27;87(13):1329-36.

Ljungqvist J et al. Serum Neurofilament Light Protein as a Marker for Diffuse Axonal Injury: Results from a Case Series Study. J Neurotrauma. 2017 Mar 1;34(5):1124-1127.

Bergman J, et al. Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS. Neurol Neuroimmunol Neuroinflamm. 2016 Aug 2;3(5).

Mattsson N, et al. Alzheimer’s Disease Neuroimaging Initiative. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer’s disease. EMBO Mol Med. 2016 Oct 4;8(10):1184-1196.

Arrambide G, et al. Neurofilament light chain level is a weak risk factor for the development of MS. Neurology. 2016 Sep 13;87(11):1076-84.

Khalil M, Salzer J. CSF neurofilament light: A universal risk biomarker in multiple sclerosis? Neurology. 2016 Sep 13;87(11):1068-9.

Bacioglu M, et al. Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. Neuron. 2016 Jul 20;91(2):494-496.

Jeppsson A, et al. Amyloid mis-metabolism in idiopathic normal pressure hydrocephalus. Fluids Barriers CNS. 2016 Jul 29;13(1):13.

Ahlgren E, et al. Association between Plasma Homocysteine Levels and Neuronal Injury in HIV Infection. PLoS One. 2016 Jul 21;11(7):e0158973.

Oeckl P, et al. Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2016 Jul-Aug;17(5-6):404-13.

Anderson AM, et al. Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals. J Neurovirol. 2017 Feb;23(1):106-112.

Eyjolfsdottir H, et al. Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer’s disease patients: application of a second-generation encapsulated cell biodelivery device. Alzheimers Res Ther. 2016 Jul 7;8(1):30.

Zetterberg H. Neurofilament Light: A Dynamic Cross-Disease Fluid Biomarker for Neurodegeneration. Neuron. 2016 Jul 6;91(1):1-3.

Lam MA, et al. Absence of systemic oxidative stress and increased CSF prostaglandin F2α in progressive MS. Neurol Neuroimmunol Neuroinflamm. 2016 Jun 30;3(4):e256.

de Flon P, et al. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. Neurology. 2016 Jul 12;87(2):141-7.

Lu CH, et al. Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016 Jun 1;3(4):e244.

Edén A, et al. Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment. PLoS One. 2016 Jun 13;11(6):e0157160.

Bacioglu M, et al. Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. Neuron. 2016 Jul 6;91(1):56-66.

Pijnenburg YA, et al. Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimers Dement (Amst). 2015 Dec 14;1(4):505-12.

Wilke C, et al. Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum. J Neurol Neurosurg Psychiatry. 2016 Nov;87(11):1270-1272.

Jespersen S, et al. Soluble CD14 in cerebrospinal fluid is associated with markers of inflammation and axonal damage in untreated HIV-infected patients: a retrospective cross-sectional study. BMC Infect Dis. 2016 Apr 21;16:176.

Kuhle J, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med. 2016 Oct 1;54(10):1655-61.

Wright PW, et al. Putamen volume and its clinical and neurological correlates in primary HIV infection. AIDS. 2016 Jul 17;30(11):1789-94.

Rojas JC, et al. Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol. 2016 Feb 1;3(3):216-25.

Novakova L, et al. Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. Mult Scler. 2017 Jan;23(1):62-71.

Racine AM, et al. Cerebrospinal fluid ratios with Aβ42 predict preclinical brain β-amyloid accumulation. Alzheimers Dement (Amst). 2016;2:27-38.

Hall S, et al. Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson’s Disease. Mov Disord. 2016 Jun;31(6):898-905.

Gisslén M, et al. Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. EBioMedicine. 2015 Nov 22;3:135-40.

Albanese M, et al. Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression. J Neuroinflammation. 2016 Feb 10;13:36.

Melah KE, et al. Cerebrospinal Fluid Markers of Alzheimer’s Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer’s Disease. J Alzheimers Dis. 2016; 50(3):873-86.

Constantinescu R, et al. Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis. Eur J Neurol. 2016 Apr;23(4):796-806.

Al Nimer F, et al. Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination. Neurol Neuroimmunol Neuroinflamm. 2016 Jan 7;3(1):e191.

Oliver JM, et al. Effect of Docosahexaenoic Acid on a Biomarker of Head Trauma in American Football. Med Sci Sports Exerc. 2016 Jun;48(6):974-82.

Kuhle J, et al. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. Mult Scler. 2016 Oct;22(12):1550-1559.

Oliver JM, et al. Serum Neurofilament Light in American Football Athletes over the Course of a Season. J Neurotrauma. 2016 Oct 1;33(19):1784-1789.

Shahim P, et al. Cerebrospinal fluid markers of central nervous system injury in decompression illness – a case-controlled pilot study. Diving Hyperb Med. 2015 Dec;45(4):240-3.

Merisson E, et al. Total-tau and neurofilament light in CSF reflect spinal cord ischaemia after endovascular aortic repair.Neurochem Int. 2016 Feb;93:1-5.

Evered L, et al. Cerebrospinal Fluid Biomarker for Alzheimer Disease Predicts Postoperative Cognitive Dysfunction.Anesthesiology. 2016 Feb;124(2):353-61.

Weydt P, et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis.Ann Neurol. 2016 Jan;79(1):152-8.

Zetterberg H, et al. Alzheimer’s Disease Neuroimaging Initiative. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. JAMA Neurol. 2016 Jan;73(1):60-7.

Janelidze S, et al. Increased CSF biomarkers of angiogenesis in Parkinson disease. Neurology. 2015 Nov 24;85(21):1834-42.

Sandberg L, et al. Vitamin D and axonal injury in multiple sclerosis. Mult Scler. 2016 Jul;22(8):1027-31.

Traenka C, et al. Serum Neurofilament Light Chain Levels Are Associated with Clinical Characteristics and Outcome in Patients with Cervical Artery Dissection. Cerebrovasc Dis. 2015;40(5-6):222-7.

Paterson RW, et al. Dissecting IWG-2 typical and atypical Alzheimer’s disease: insights from cerebrospinal fluid analysis. J Neurol. 2015 Dec;262(12):2722-30.

Vågberg M, et al. Levels and Age Dependency of Neurofilament Light and Glial Fibrillary Acidic Protein in Healthy Individuals and Their Relation to the Brain Parenchymal Fraction. PLoS One. 2015 Aug 28;10(8):e0135886.

Steinacker P, et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry. 2016 Jan;87(1):12-20.

Modvig S, et al. Cerebrospinal fluid neurofilament light chain levels predict visual outcome after optic neuritis. Mult Scler. 2016 Apr;22(5):590-8.

Menke RA, et al. CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann Clin Transl Neurol. 2015 Jul;2(7):748-55.

Bäckström DC, et al. Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease. JAMA Neurol. 2015 Oct;72(10):1175-82.

Mäkitalo S, et al. The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer’s disease. AIDS Res Ther. 2015 Jul 14;12:23.

Al Nimer F, et al. Comparative Assessment of the Prognostic Value of Biomarkers in Traumatic Brain Injury Reveals an Independent Role for Serum Levels of Neurofilament Light. PLoS One. 2015 Jul 2;10(7).

Herbert MK, et al. CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders. Front Neurol. 2015 May 5;6:91.

Peluso MJ, et al. Absence of Cerebrospinal Fluid Signs of Neuronal Injury Before and After Immediate Antiretroviral Therapy in Acute HIV Infection. J Infect Dis. 2015 Dec 1;212(11):1759-67.

Rolstad S, et al. Cognitive performance and cerebrospinal fluid biomarkers of neurodegeneration: a study of patients with bipolar disorder and healthy controls. PLoS One. 2015 May 8;10(5).

Lu CH, et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015 Jun 2;84(22):2247-57.

Stilund M, et al. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel. PLoS One. 2015 Apr 10;10(4):e0119681.

Wild EJ, et al. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington’s disease patients. J Clin Invest. 2015 May;125(5):1979-86.

Aeinehband S, et al. Complement component C3 and butyrylcholinesterase activity are associated with neurodegeneration and clinical disability in multiple sclerosis. PLoS One. 2015 Apr 2;10(4):e0122048.

Kuhle J, et al. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology. 2015 Apr 21;84(16):1639-43.

Martínez MA, et al. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult Scler. 2015 Apr;21(5):550-61.

Disanto G, et al. International Clinically Isolated Syndrome Study Group.. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):126-9.

Modvig S, et al. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis. Mult Scler. 2015 Dec;21(14):1761-70.

Limberg M, Neurofilament Light Chain Determination from Peripheral Blood Samples. Methods Mol Biol. 2016;1304:93-8.

Rolstad S, et al. Differential Impact of Neurofilament Light Subunit on Cognition and Functional Outcome in Memory Clinic Patients with and without Vascular Burden. J Alzheimers Dis. 2015;45(3):873-81.

Magdalinou NK, et al. A panel of  nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2015 Nov;86(11):1240-7.

Peterson J, et al. Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection. PLoS One. 2014 Dec 26;9(12):e116081.

Bjerke M, et al. Cerebrovascular Biomarker Profile Is Related to White Matter Disease and Ventricular Dilation in a LADIS Substudy. Dement Geriatr Cogn Dis Extra. 2014 Oct 21;4(3):385-94.

Hall S, et al. CSF biomarkers and clinical progression of Parkinson disease. Neurology. 2015 Jan 6;84(1):57-63.

Skillbäck T, et al. CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology. 2014 Nov 18;83(21):1945-53.

Villar LM, et al. Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis. Eur J Neurol. 2015 Aug;22(8):1169-75.

Trentini A, et al. N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. J Neurol. 2014 Dec;261(12):2338-43.

Tortorella C, et al. Cerebrospinal fluid neurofilament tracks fMRI correlates of attention at the first attack of multiple sclerosis.Mult Scler. 2015 Apr;21(4):396-401.

Neselius S, et al. Neurological assessment and its relationship to CSF biomarkers in amateur boxers. PLoS One. 2014 Jun 18;9(6):e99870.

Kuhle J, et al. Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. J Neurol Neurosurg Psychiatry. 2015 Mar;86(3):273-9.

Hjalmarsson C, et al. Neuronal and glia-related biomarkers in cerebrospinal fluid of patients with acute ischemic stroke. J Cent Nerv Syst Dis. 2014 May 19;6:51-8.

Neselius S, et al. Monitoring concussion in a knocked-out boxer by CSF biomarker analysis. Knee Surg Sports Traumatol Arthrosc. 2015 Sep;23(9):2536-9.

Tortelli R, et al. Cerebrospinal fluid neurofilament light chain levels: marker of progression to generalized amyotrophic lateral sclerosis. Eur J Neurol. 2015 Jan;22(1):215-8.

Jakobsson J, et al. Elevated concentrations of neurofilament light chain in the cerebrospinal fluid of bipolar disorder patients.Neuropsychopharmacology. 2014 Sep;39(10):2349-56.

Romme Christensen J, et al. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial.Neurology. 2014 Apr 29;82(17):1499-507.

Pyykkö OT, et al. Cerebrospinal fluid biomarker and brain biopsy findings in idiopathic normal pressure hydrocephalus. PLoS One. 2014 Mar 17;9(3):e91974.

Burman J, et al. Assessing tissue damage in multiple sclerosis: a biomarker approach. Acta Neurol Scand. 2014 Aug;130(2):81-9.

Jessen Krut J, et al. Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients. PLoS One. 2014 Feb 11;9(2):e88591.

Skillbäck T, et al. Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples.Alzheimers Res Ther. 2013 Oct 14;5(5):47.

Anckarsäter R, et al. Non-neurological surgery and cerebrospinal fluid biomarkers for neuronal and astroglial integrity. J Neural Transm (Vienna). 2014 Jun;121(6):649-53.

Koel-Simmelink MJ, et al. The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA. J Immunol Methods. 2014 Jan 15;402(1-2):43-9.

Neselius S, et al. Increased CSF levels of phosphorylated neurofilament heavy protein following bout in amateur boxers. PLoS One. 2013 Nov 15;8(11):e81249.

Scherling CS, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration.Ann Neurol. 2014 Jan;75(1):116-26.

Rosén C, et al. Cerebrospinal fluid biomarkers in cardiac arrest survivors. Resuscitation. 2014 Feb;85(2):227-32.

Modvig S, et al. Relationship between cerebrospinal fluid biomarkers for inflammation, demyelination and neurodegeneration in acute optic neuritis. PLoS One. 2013 Oct 8;8(10):e77163.

Fialová L, et al. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis. J Neuroimmunol. 2013 Sep 15;262(1-2):113-20.

Shahim P, et al. Cerebrospinal fluid braininjury biomarkers in children: a multicenter study. Pediatr Neurol. 2013 Jul;49(1):31-39.e2.

Kuhle Jet al. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Acta Neurol Scand. 2013 Dec;128(6):e33-6.

Ragnarsson O, et al. Neurodegenerative and inflammatory biomarkers in cerebrospinal fluid in patients with Cushing’s syndrome in remission. Eur J Endocrinol. 2013 Jul 6;169(2):211-5.

Landqvist Waldö M, et al. Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia.BMC Neurol. 2013 May 29;13:54.

Axelsson M, et al. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Mult Scler. 2014 Jan;20(1):43-50.

Khademi M, et al. Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers. PLoS One. 2013 May 7;8(5):e63172.

Kuhle J, et al. A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult Scler. 2013 Oct; 19(12):1597-603.

Jeppsson A, et al. Idiopathic normal-pressure hydrocephalus: pathophysiology and diagnosis by CSF biomarkers. Neurology. 2013 Apr 9;80(15):1385-92.

Grahn A, et al. Cerebrospinal fluid biomarkers in patients with varicella-zoster virus CNS infections. J Neurol. 2013 Jul;260(7):1813-21.

Peluso MJ, et al. Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis. 2013 Jun 1;207(11):1703-12.

Rana OR, et al. Neurofilament light chain as an early and sensitive predictor of long-term neurological outcome in patients after cardiac arrest. Int J Cardiol. 2013 Sep 30;168(2):1322-7.

Jonsson M, et al. Low cerebrospinal fluid sulfatide predicts progression of white matter lesions: The LADIS study. Dement Geriatr Cogn Disord. 2012;34(1):61-7.

Khalil M, et al. CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome. Mult Scler. 2013 Apr;19(4):436-42.

Bendlin BB, et al. CSF T-Tau/Aβ42 predicts white matter microstructure in healthy adults at risk for Alzheimers disease.PLoS One. 2012;7(6):e37720.

Reinsfelt B, et al. Cerebrospinal fluid markers of brain injury, inflammation, and blood-brain barrier dysfunction in cardiac surgery. Ann Thorac Surg. 2012 Aug;94(2):549-55.

Tortelli R, et al. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression. Eur J Neurol. 2012 Dec;19(12):1561-7.

Angel TE, et al. The cerebrospinal fluid proteome in HIV infection: change associated with disease severity. Clin Proteomics. 2012 Mar 20;9(1):3.

Magnoni S, et al. Tau elevations in the brain extracellular space correlate with reduced amyloid-β levels and predict adverse clinical outcomes after severe traumatic brain injury. Brain. 2012 Apr;135(Pt 4):1268-80.

Wallin A, et al. Progression from mild to pronounced MCI is not associated with cerebrospinal fluid biomarker deviations.Dement Geriatr Cogn Disord. 2011;32(3):193-7.

Bech S, et al. Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes. Parkinsonism Relat Disord. 2012 Jan;18(1):69-72.

Bjerke M, et al. Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer’s disease. J Alzheimers Dis. 2011;27(3):665-76.

Gunnarsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol. 2011 Jan;69(1):83-9.

Axelsson M, et al. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis. J Neurol. 2011 May;258(5):882-8.

Constantinescu R, et al. Light subunit of neurofilament triplet protein in the cerebrospinal fluid after subthalamic nucleus stimulation for Parkinson’s disease. Acta Neurol Scand. 2011 Sep;124(3):206-10.

Zanier ER, et al. Neurofilament light chain levels in ventricular cerebrospinal fluid after acute aneurysmal subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry. 2011 Feb;82(2):157-9.

van Eijk JJ, et al. CSF neurofilament proteins levels are elevated in sporadic Creutzfeldt-Jakob disease. J Alzheimers Dis. 2010;21(2):569-76.

Gudmundsson P, et al. Is there a CSF biomarker profile related to depression in elderly women? Psychiatry Res. 2010 Apr 30;176(2-3):174-8.

Salzer J, et al. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler. 2010 Mar;16(3):287-92.

Bjerke M, et al. Subcortical vascular dementia biomarker pattern in mild cognitive impairment. Dement Geriatr Cogn Disord. 2009;28(4):348-56.

Petzold A, et al. Neurofilament ELISA validation. J Immunol Methods. 2010 Jan 31;352(1-2):23-31.

Jonsson M, et al. Cerebrospinal fluid biomarkers of white matter lesions – cross-sectional results from the LADIS study. Eur J Neurol. 2010 Mar;17(3):377-82.

Gavhed D, et al. Biomarkers in the cerebrospinal fluid and neurodegeneration in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2009 Dec 15;53(7):1264-70.

Constantinescu R, et al. Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson’s disease and atypical Parkinsonian disorders. Parkinsonism Relat Disord. 2010 Feb;16(2):142-5.

Teunissen CE, et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology. 2009 Apr 14;72(15):1322-9.

Petzold A, et al. Longitudinal one-year study of levels and stoichiometry of neurofilament heavy and light chain concentrations in CSF in patients with multiple system atrophy. J Neurol Sci. 2009 Apr 15;279(1-2):76-9.

Constantinescu R, et al. Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington’s disease. Parkinsonism Relat Disord. 2009 Mar;15(3):245-8.